Php240 - Health Technology Assessments of Bevacizumab Biosimilars: Could a Demonstration of Cost-Effectiveness Change the Recommendation for Reimbursement Versus the Originator?
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1134
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV